VGYAAN Pharmaceuticals Receives Tentative Approval from US FDA for Selexipag Tablets, Generic Equivalent to UPTRAVI®

March 6, 2023

Skillman, NJ -- VGYAAN Pharmaceuticals today announced that it has received tentative approval from US FDA for Selexipag Tablets (200 mcg, 400 mcg, 600 mcg, 800 mcg, 1,000 mcg, 1,200 mcg, 1,400 mcg, and 1,600 mcg), the generic equivalent to UPTRAVI®.

Selexipag is used in adults to treat pulmonary arterial hypertension (PAH) to delay disease progression and reduce the risk of hospitalization for PAH. Selexipag is a prostacyclin receptor agonist.

“We are truly pleased to receive this tentative approval for Selexipag and add to our growing product pipeline. Approval of such a complex product further validates VGYAAN’s robust capabilities in identifying products and selecting strategic partners,” commented Nailesh Bhatt, Chief Executive Officer of VGYAAN Pharmaceuticals.

“This is a major milestone for VGYAAN Pharmaceuticals given the technical, intellectual property, and supply chain challenges associated with this product. We are proud of our team, partners, and advisors who collaborated with us on this product and thank them for their contributions,” added Nimisha Vyas Bhatt, Chief Operating Officer of VGYAAN Pharmaceuticals.

About VGYAAN Pharmaceuticals

VGYAAN Pharmaceuticals LLC, headquartered in Skillman, New Jersey is focused on developing and commercializing clinically critical drugs. VGYAAN is fully equipped and licensed to perform sales, marketing, and distribution of high quality and affordable drugs in the US with capabilities to serve clients across a wide range of channels. Our product portfolio includes solid orals and injectables in a broad range of therapeutic areas.

For more information, please visit www.vgyaan.com or contact media@vgyaan.com.